$NVCR
NovoCure Ltd Stock $nvcr

$nvcr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000164511324000019 Filed on July 25, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$155.1M	$150.4M
YoY Change	21.81%	19.28%
Cost Of Revenue	$35.37M	$34.65M
YoY Change	10.22%	1.87%
Gross Profit	$119.7M	$115.7M
YoY Change	25.72%	25.72%
Gross Profit Margin	77.19%	76.95%
Selling, General & Admin	$99.93M	$94.33M
YoY Change	0.08%	-4.98%
% of Gross Profit	83.47%	81.53%
Research & Development	$51.88M	$54.96M
YoY Change	-3.25%	-0.85%
% of Gross Profit	43.34%	47.5%
Depreciation & Amortization	$2.458M	$2.858M
YoY Change	-12.53%	5.03%
% of Gross Profit	2.05%	2.47%
Operating Expenses	$151.8M	$149.3M
YoY Change	-1.08%	-3.5%
Operating Profit	-$32.09M	-$33.58M
YoY Change	-44.9%	-46.41%
Interest Expense	$10.51M	$10.85M
YoY Change	5.07%	23.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$21.59M	-$22.73M
YoY Change	-55.24%	-57.83%
Income Tax	$8.985M	$10.65M
% Of Pretax Income
Net Earnings	-$30.57M	-$33.38M
YoY Change	-38.22%	-41.87%
Net Earnings / Revenue	-19.71%	-22.2%
Basic Earnings Per Share	-$0.28	-$0.31
Diluted Earnings Per Share	-$0.28	-$0.31
COMMON SHARES
Basic Shares Outstanding	108.2M shares	107.6M shares
Diluted Shares Outstanding	108.2M shares	107.7M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$959.9M	$951.2M
YoY Change	4.2%	1.1%
Cash & Equivalents	$185.4M	$164.8M
Short-Term Investments	$774.5M	$788.4M
Other Short-Term Assets	$3.777M	$3.647M
YoY Change	122.18%	606.78%
Inventory	$39.10M	$40.44M
Prepaid Expenses
Receivables	$67.06M	$64.70M
Other Receivables	$25.44M	$32.86M
Total Short-Term Assets	$1.095B	$1.093B
YoY Change	4.51%	2.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$73.25M	$66.48M
YoY Change	60.77%	-15.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.22M	$12.06M
YoY Change	-1.55%	-17.22%
Total Long-Term Assets	$126.7M	$119.3M
YoY Change	28.84%	27.6%
TOTAL ASSETS
Total Short-Term Assets	$1.095B	$1.093B
Total Long-Term Assets	$126.7M	$119.3M
Total Assets	$1.222B	$1.212B
YoY Change	6.6%	4.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$91.32M	$90.17M
YoY Change	14.58%	9.25%
Accrued Expenses
YoY Change
Deferred Revenue	$14.87M	$15.61M
YoY Change
Short-Term Debt	$557.3M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$735.0M	$169.2M
YoY Change	367.67%	12.72%
LONG-TERM LIABILITIES
Long-Term Debt	$97.15M	$653.5M
YoY Change	-82.9%	15.22%
Other Long-Term Liabilities	$18.00K	$18.00K
YoY Change	-76.0%	-99.93%
Total Long-Term Liabilities	$126.2M	$681.2M
YoY Change	-78.81%	14.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$735.0M	$169.2M
Total Long-Term Liabilities	$126.2M	$681.2M
Total Liabilities	$861.2M	$850.4M
YoY Change	14.42%	14.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.088B	-$1.058B
YoY Change	15.96%	18.98%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$360.8M	$361.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.222B	$1.212B
YoY Change	6.6%	4.59%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$30.57M	-$33.38M
YoY Change	-38.22%	-41.87%
Depreciation, Depletion And Amortization	$2.458M	$2.858M
YoY Change	-12.53%	5.03%
Cash From Operating Activities	$10.38M	-$1.720M
YoY Change	-153.72%	-92.44%
INVESTING ACTIVITIES
Capital Expenditures	$10.68M	$11.45M
YoY Change	47.29%	65.14%
Acquisitions
YoY Change
Other Investing Activities	$20.88M	-$363.0M
YoY Change	-14.83%	5110.94%
Cash From Investing Activities	$10.19M	-$374.4M
YoY Change	-40.94%	2594.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00	$12.91M
YoY Change		430333.33%
Cash From Financing Activities	$100.0K	$87.32M
YoY Change	-91.46%	1063.92%
NET CHANGE
Cash From Operating Activities	$10.38M	-$1.720M
Cash From Investing Activities	$10.19M	-$374.4M
Cash From Financing Activities	$100.0K	$87.32M
Net Change In Cash	$20.76M	-$288.9M
YoY Change	-2213.65%	891.76%
FREE CASH FLOW
Cash From Operating Activities	$10.38M	-$1.720M
Capital Expenditures	$10.68M	$11.45M
Free Cash Flow	-$307.0K	-$13.17M
YoY Change	-98.84%	-55.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1422903000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1353468000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3515000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5469000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1057638000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-985503000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	361750000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	362496000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1212170000	usd
CY2024Q2	us-gaap	Revenues Revenues	150356000	usd
CY2023Q2	us-gaap	Revenues Revenues	126051000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	34654000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	34018000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37711000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40778000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	149282000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	154693000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-33580000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-62660000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-33375000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-57418000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107700284	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107700284	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-33375000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-57418000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	102000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	529000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	68000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-530000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-113000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34084000	usd
CY2024Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	213000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1322000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38760000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	359355000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31830000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2187000	usd
CY2024Q2	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	1121000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	632000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-33375000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	361750000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441170000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39084000	usd
CY2023Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	5211000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-258000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53061000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	432146000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32740000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2883000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	710000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-57418000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	415683000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-33375000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-57418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72135000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-110479000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-207043000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2858000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2721000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5673000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5443000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10969000	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-349000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1170000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1273000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	50000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-95000	usd
CY2024Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	140000	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	136000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	334000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	493000	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	31830000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	32740000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-161000	usd
CY2024Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-6854000	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-5075000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-12235000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-9131000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-23084000	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1888000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1452000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2762000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4170000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8919000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4889000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1920000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-6063000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	386000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9548000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	207000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8697000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10257000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14869000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1829000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1701000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3594000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4859000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-9781000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1720000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22737000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33294000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39464000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73336000	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11446000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6931000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23230000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13019000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27093000	usd
CY2024Q2	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	160000000	usd
CY2023Q2	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	314597000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	640884000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	1214982000	usd
CY2024Q2	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	522994000	usd
CY2023Q2	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	321563000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	522994000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	559475000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-374440000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13897000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-128224000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	68390000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	184148000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2187000	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2883000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2187000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2883000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4416000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	457363000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115834000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115834000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	90171000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	94391000	usd
CY2024Q2	nvcr	Other Accounts Payable Lease Liabilities And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent	79007000	usd
CY2023Q4	nvcr	Other Accounts Payable Lease Liabilities And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent	84724000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	169178000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	179115000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21731000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	681242000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	604518000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	850420000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	783633000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1146129000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	115702000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	92033000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54955000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55427000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22729000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53904000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10646000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3514000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106289073	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106289073	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106391178	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106391178	shares
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32743000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56708000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	362496000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157494000	usd
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108013830	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108013830	shares
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	556508000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	568822000	usd
CY2024Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	96962000	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27420000	usd
CY2024Q2	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	6023000	usd
CY2023Q4	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	8258000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	56616000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	58488000	usd
CY2024Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10851000	usd
CY2023Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	8756000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107483241	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107483241	shares
CY2023Q2	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	4622000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	262000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	65914000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	71824000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	115608000	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-653000	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-914000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1266000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-787000	usd
CY2024Q2	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	11119000	usd
CY2023Q2	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	-6941000	usd
	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	14394000	usd
	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	-21452000	usd
CY2023	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	-29414000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4072000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	418000000	usd
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1003741000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	96922000	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	96922000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2024Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12913000	usd
CY2023Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12913000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000	usd
CY2024Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1121000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4622000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1334000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9833000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11381000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87317000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7502000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87530000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12706000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15787000	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-77000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-13000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-133000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-288920000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29145000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-74121000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41660000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	126730000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186639000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242564000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168443000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157494000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168443000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157494000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242564000	usd
CY2024Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7501000	usd
CY2023Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5831000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10415000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7543000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	13665000	usd
CY2024Q2	us-gaap	Interest Paid Net InterestPaidNet	1968000	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	1970000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	6000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164796000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156978000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164796000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156978000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	240821000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3647000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	516000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3647000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	516000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1743000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168443000	usd
CY2024Q2	nvcr	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Disposals RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfDisposals	-1649000	usd
CY2023Q2	nvcr	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Disposals RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfDisposals	2333000	usd
	nvcr	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Disposals RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfDisposals	-1367000	usd
	nvcr	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Disposals RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfDisposals	5784000	usd
CY2023	nvcr	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Disposals RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfDisposals	18063000	usd
CY2024Q2	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	401000	usd
CY2023Q2	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	401000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	1714000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Concentration Risks. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally and the total value invested at any one institution is limited pursuant to the Company's investment policy. These investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand according to the terms of the securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's trade receivables are due from numerous governments and federal and state agencies that are paid from their respective budgets, and from hundreds of health insurance companies. The Company does not believe that there are significant default risks associated with these governments, agencies and health insurance companies based upon the Company's historical experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></div>
CY2024Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	578193000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	150000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	300000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	578043000	usd
CY2024Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	578193000	usd
CY2024Q2	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Amortized Cost CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesAmortizedCost	951186000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain	150000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	300000	usd
CY2024Q2	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Fair Value CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesFairValue	951036000	usd
CY2024Q2	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecurities	951186000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	520326000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	554000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	259000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	520621000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	520326000	usd
CY2023Q4	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Amortized Cost CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesAmortizedCost	910616000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain	554000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	259000	usd
CY2023Q4	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Fair Value CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesFairValue	910911000	usd
CY2023Q4	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecurities	910616000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9585000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10265000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11854000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9796000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19003000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	18091000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	40442000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	38152000	usd
CY2024Q2	us-gaap	Deposits Assets DepositsAssets	2797000	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	2848000	usd
CY2024Q2	us-gaap	Contractual Obligation ContractualObligation	3155000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	3216000	usd
CY2024Q2	us-gaap	Revenues Revenues	150356000	usd
CY2023Q2	us-gaap	Revenues Revenues	126051000	usd
	us-gaap	Revenues Revenues	288859000	usd
	us-gaap	Revenues Revenues	248233000	usd
CY2023	us-gaap	Revenues Revenues	509338000	usd
CY2024Q2	us-gaap	Revenues Revenues	150356000	usd
CY2023Q2	us-gaap	Revenues Revenues	126051000	usd
	us-gaap	Revenues Revenues	288859000	usd
	us-gaap	Revenues Revenues	248233000	usd
CY2023	us-gaap	Revenues Revenues	509338000	usd
CY2024Q2	nvcr	Accounts Receivable Excluding Unbilled Receivables AccountsReceivableExcludingUnbilledReceivables	59869000	usd
CY2023Q4	nvcr	Accounts Receivable Excluding Unbilled Receivables AccountsReceivableExcludingUnbilledReceivables	56970000	usd
CY2024Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4834000	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4251000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15605000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16224000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	16224000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	18028000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	18028000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8539507	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3593899	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.46
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172463	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.74
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	431933	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	49.89
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11529010	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.51
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6897941	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	35.39
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31830000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32740000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65914000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	71824000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	115608000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-33375000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-57418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72135000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-110479000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-207043000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107700284	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106289073	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107483241	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105979791	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106391178	shares
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14028652	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8483336	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12575762	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7733239	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8535785	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.95
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.95
CY2024Q2	us-gaap	Noncurrent Assets NoncurrentAssets	78196000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	62863000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	200	employee
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2024Q2	us-gaap	Restructuring Costs RestructuringCosts	-27000	usd
CY2023Q2	us-gaap	Restructuring Costs RestructuringCosts	0	usd
	us-gaap	Restructuring Costs RestructuringCosts	2003000	usd
	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2023	us-gaap	Restructuring Costs RestructuringCosts	6231000	usd
CY2024Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	327000	usd
CY2023Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	0	usd
	us-gaap	Payments For Restructuring PaymentsForRestructuring	5455000	usd
	us-gaap	Payments For Restructuring PaymentsForRestructuring	0	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	2753000	usd
CY2024Q2	nvcr	Employee Benefit And Share Based Payment Arrangement Reversal Of Accrual EmployeeBenefitAndShareBasedPaymentArrangementReversalOfAccrual	0	usd
	nvcr	Employee Benefit And Share Based Payment Arrangement Reversal Of Accrual EmployeeBenefitAndShareBasedPaymentArrangementReversalOfAccrual	369000	usd
CY2023	nvcr	Employee Benefit And Share Based Payment Arrangement Reversal Of Accrual EmployeeBenefitAndShareBasedPaymentArrangementReversalOfAccrual	3041000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	330000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	1991000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	9313000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
nvcr-20240630_cal.xml	Edgar Link	unprocessable
nvcr-20240630_def.xml	Edgar Link	unprocessable
0001645113-24-000019-index-headers.html	Edgar Link	pending
0001645113-24-000019-index.html	Edgar Link	pending
0001645113-24-000019.txt	Edgar Link	pending
0001645113-24-000019-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvcr-20240630.htm	Edgar Link	pending
nvcr-20240630.xsd	Edgar Link	pending
nvcr-20240630xexx311.htm	Edgar Link	pending
nvcr-20240630xexx312.htm	Edgar Link	pending
nvcr-20240630xexx321.htm	Edgar Link	pending
nvcr-20240630xexx322.htm	Edgar Link	pending
nvcr-20240630_g1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
nvcr-20240630_lab.xml	Edgar Link	unprocessable
nvcr-20240630_pre.xml	Edgar Link	unprocessable
nvcr-20240630_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVCR
NovoCure Ltd Stock $nvcr

2024 Q3 Form 10-Q Financial Statement

#000164511324000019 Filed on July 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR NovoCure Ltd Stock $nvcr

2024 Q3 Form 10-Q Financial Statement

#000164511324000019 Filed on July 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR
NovoCure Ltd Stock $nvcr